Achieve Life Sciences (ACHV) EPS (Weighted Average and Diluted) (2010 - 2026)
Achieve Life Sciences (ACHV) recorded quarterly EPS (Weighted Average and Diluted) of -$0.19 in Q1 2026, up 26.92% on a QoQ basis from -$0.26 in Q4 2025, and up 48.65% year-over-year from -$0.13 in Q1 2025.
Achieve Life Sciences (ACHV) EPS (Weighted Average and Diluted) (2010 - 2026) Analysis & Trends
Achieve Life Sciences has disclosed EPS (Weighted Average and Diluted) across 9 years of filings, most recently posting -$0.19 for Q1 2026.
- Quarterly EPS (Weighted Average and Diluted) rose 48.65% year-over-year to -$0.19 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.1 (up 17.91% YoY) and the FY2025 annual result came in at -$1.25, down 0.81% from the prior year.
- EPS (Weighted Average and Diluted) rose to -$0.19 in Q1 2026, from -$0.26 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at -$0.19 in Q1 2026 and troughed at -$1.35 in Q3 2022.
- A 5-year average of -$0.48 and a median of -$0.36 in 2024 frame the typical range for EPS (Weighted Average and Diluted).
- Annual changes were most pronounced in 2022 — EPS (Weighted Average and Diluted) tumbled 90.14% — and 2023, when it soared 74.81%.
- Tracing ACHV's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.76 in 2022, then soared by 68.42% to -$0.24 in 2023, then plunged by 50.0% to -$0.36 in 2024, then advanced by 27.78% to -$0.26 in 2025, then advanced by 26.92% to -$0.19 in 2026.
- Business Quant data shows ACHV's EPS (Weighted Average and Diluted) at -$0.19 in Q1 2026, -$0.26 in Q4 2025, and -$0.28 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 0.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -0.61 |
| 10 | Achieve Life Sciences | 93.71 Mn | 63.22 Mn | - | -0.19 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.19 |
| Dec 31, 2025 | -0.26 |
| Sep 30, 2025 | -0.28 |
| Jun 30, 2025 | -0.37 |
| Mar 31, 2025 | -0.37 |
| Dec 31, 2024 | -0.36 |
| Sep 30, 2024 | -0.36 |
| Jun 30, 2024 | -0.25 |
| Mar 31, 2024 | -0.26 |
| Dec 31, 2023 | -0.24 |
| Sep 30, 2023 | -0.34 |
| Jun 30, 2023 | -0.43 |
| Mar 31, 2023 | -0.50 |
| Dec 31, 2022 | -0.76 |
| Sep 30, 2022 | -1.35 |
| Jun 30, 2022 | -1.08 |
| Mar 31, 2022 | -0.80 |
| Dec 31, 2021 | -0.69 |
| Sep 30, 2021 | -0.71 |
| Jun 30, 2021 | -1.53 |